|
|
 Previous Article | Table of Contents | Next Article 
Elevated soluble interleukin-2 receptor in childhood hemophagocytic
histiocytic syndromes
DM Komp, J McNamara and P Buckley
Department of Pediatrics, Howard Hughes Medical Institute, New Haven, CT
06510.
The serum of children with untreated hemophagocytic syndromes contains
elevated levels (23,600 to 75,200 U/mL) of soluble interleukin-2 receptor
(SIL2R) that returns toward normal with clinical improvement. These levels
are in excess of levels previously reported for benign conditions. They are
as high as levels reported for HTLV-1-associated adult T-cell leukemia
(HATL) and hairy cell leukemia (HCL) in adults and some children with
poor-prognosis non-T, non-B, acute lymphoblastic leukemia (ALL). Serum
SIL-2R is a marker of disease activity that has the potential to identify
infants at risk for the inherited form of the disease before the disease is
clinically expressed.
Volume 73,
Issue 8,
pp. 2128-2132,
06/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Ponticelli and O. D. C. Alberighi
Haemophagocytic syndrome--a life-threatening complication of renal transplantation
Nephrol. Dial. Transplant.,
September 1, 2009;
24(9):
2623 - 2627.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Li
Which Children with JIA Are At Risk for a Potentially Fatal Complication?
AAP Grand Rounds,
September 1, 2007;
18(3):
29 - 30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mazodier, V. Marin, D. Novick, C. Farnarier, S. Robitail, N. Schleinitz, V. Veit, P. Paul, M. Rubinstein, C. A. Dinarello, et al.
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Blood,
November 15, 2005;
106(10):
3483 - 3489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-I. Henter, A. Samuelsson-Horne, M. Arico, R. M. Egeler, G. Elinder, A. H. Filipovich, H. Gadner, S. Imashuku, D. Komp, S. Ladisch, et al.
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation
Blood,
September 18, 2002;
100(7):
2367 - 2373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Morrell, M. A. Pepping, J. P. Scott, N. B. Esterly, and B. A. Drolet
Cutaneous Manifestations of Hemophagocytic Lymphohistiocytosis
Arch Dermatol,
September 1, 2002;
138(9):
1208 - 1212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Endo, K. Kanno, M. Takahashi, K.-i. Yamaguchi, Y. Kohno, and T. Fujita
Molecular Basis of Human Complement C1s Deficiency
J. Immunol.,
February 15, 1999;
162(4):
2180 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, M.-L. Sulis, N. Jabado, S. Blanche, A. Fischer, and M. Tardieu
Frequency and Severity of Central Nervous System Lesions in Hemophagocytic Lymphohistiocytosis
Blood,
February 1, 1997;
89(3):
794 - 800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
